The head of Gapminder, whose mission is to fight ignorance with a fact-based world view, talks with Gavi about data and COVID-19.

Living Goods saves lives by supporting digitally empowered community health workers who deliver care

With surveys using antibody tests yielding disappointing results, there are growing concerns that fewer people may have already been infected with SARS-CoV-2 than was previously hoped. Yet antibodies are only part of our immune system’s response…

This article is a summary of an online conversation hosted by the Gavi CSO Constituency in partnership with ACTION, Gavi, the Vaccine Alliance, RESULTS UK & Save the Children.

Routine immunisation has slowed in many Gavi-supported countries around the world. Here, researchers writing in The Lancet, including a Gavi scientist, look at the effect of lockdown on vaccination programmes in Karachi, Pakistan …

Global technology company TransferWise and a donor which asked to remain anonymous made significant financial commitments to Gavi’s Advance Market Commitment for COVID-19 Vaccines (Gavi COVAX AMC)

Across Gavi-eligible countries, we have seen a consistent increase in cases since March 2020. Within the month of June alone, the number of cases has more than doubled, with 70 out of 73 Gavi-eligible countries reporting over 1 million confirmed…

As of 27 June 2020, there have been 513 tests carried out in the camps, with 49 confirmed cases.

The first African clinical trial for a COVID-19 vaccine has started in South Africa, run by the University of the Witwatersrand, Johannesburg (Wits).

'Global Goal: Unite for Our Future' mobilized over $6.9 billion to help the world’s most vulnerable.

On 25 June, the outbreak of Ebola in the Democratic Republic of the Congo that has raged for more than 2 years is over. What does this mean for the country and what can it teach us about ending the COVID-19 pandemic?

Gavi Board shows support for continued work on COVAX Facility: a global, coordinated mechanism designed to ensure rapid and equitable access to safe and efficacious COVID-19 vaccines to as broad a global population as possible